Diagnóstico e terapêutica empregados na degeneração mixomatosa valvar em cães – uma revisão literária
DOI:
https://doi.org/10.34188/bjaerv8n4-054Palavras-chave:
degeneração mixomatosa valvar, cães, diagnóstico, terapêuticaResumo
Baseado em uma revisão da literatura científica, este trabalho analisa o diagnóstico e tratamento da degeneração mixomatosa valvar mitral (DMVM) em cães. O objetivo principal foi compreender os métodos diagnósticos e terapêuticos para essa cardiopatia comum e grave. A importância do diagnóstico precoce e da classificação em estágios segundo o “American College of Veterinary Internal Medicine” (ACVIM) é crucial, pois guiam o tratamento. A revisão detalhada do uso de exame físico, radiografia e ecocardiograma para cada fase da doença foi realizada. As abordagens terapêuticas, incluindo o uso de medicamentos, são discutidas para cada estágio. Em conclusão, a chave para um tratamento bem-sucedido é uma abordagem multidisciplinar e personalizada, seguindo as diretrizes atuais para melhorar a qualidade de vida e a longevidade de cães com DMVM.
Referências
ACIERNO, M. J. et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. Journal of Veterinary Internal Medicine, [S. l.], v. 32, n. 6, p. 1803–1822, 2018. DOI: 10.1111/jvim.15331. Disponível em: https://doi.org/10.1111/jvim.15331. Acesso em: 10 jul. 2025.
ANGELO, A. L. D. Cardiologia. In: LIMA, F. B. (org.). Clínica Médica de Pequenos Animais. 1. ed. Salvador, BA: Editora Sanar, 2020. p. 253-289.
BAGARDI, M. et al. Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. Polish Journal of Veterinary Sciences, Olsztyn, v. 24, n. 1, p. 109–118, mar. 2021. DOI: 10.24425/pjvs.2021.136799.
BAISAN, R. A.; VULPE, V. Vertebral Heart Score and Vertebral Left Atrial Size as Radiographic Measurements for Cardiac Size in Dogs: A Literature Review. Animals, Basel, v. 15, n. 5, p. 683, 2025. Disponível em: https://www.mdpi.com/2076-2615/15/5/683.
BENOWITZ, N. L. Antihypertensive agents. In: VANDERAH, T. W. (ed.). Katzung’s Basic & Clinical Pharmacology. 16. ed. New York: McGraw Hill, 2024. p. 177–199.
BESCHE, B. et al. Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study. Journal of Veterinary Internal Medicine, v. 34, n. 5, p. 1746–1758, 2020. Disponível em: https://onlinelibrary.wiley.com/doi/full/10.1111/jvim.15864. Acesso em: 06 ago. 2025.
BORGARELLI, M. et al. DELay of appearance of sYmptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: the DELAY study. Journal of Veterinary Cardiology, v. 27, p. 34–53, 2020. DOI: https://doi.org/10.1016/j.jvc.2019.12.002.
BORGARELLI, M.; BUCHANAN, J. W. Historical review, epidemiology and natural history of degenerative mitral valve disease. Journal of Veterinary Cardiology, Amsterdam, v. 14, n. 1, p. 93–101, mar. 2012. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S1760273412000239. Acesso em: 16 jul. 2025.
BOSWOOD, A. et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. Journal of Veterinary Internal Medicine, [s. l.], v. 30, n. 6, p. 1765-1779, set. 2016. DOI: 10.1111/jvim.14586. Disponível em: https://doi.org/10.1111/jvim.14586. Acesso em: 21 jul. 2025.
CHETBOUL, V. et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. Journal of Veterinary Internal Medicine, Hoboken, NJ, v. 21, n. 4, p. 742–753, jul./ago. 2007. DOI: 10.1111/j.1939-1676.2007.tb03016.x.
COFFMAN, M. et al. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). Journal of Veterinary Internal Medicine, v. 35, n. 4, p. 1673–1687, 2021. DOI: 10.1111/jvim.16155. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/jvim.16155. Acesso em: 22 jul. 2025.
ELLIS-REIS, R. E.; VISSER, L. C.; HSUE, W.; SHARPE, A. N.; KAPLAN, J. L. Echocardiographic evaluation of regurgitant fraction in dogs with subclinical myxomatous mitral valve disease: Method comparison, effects of pimobendan, and reproducibility. Journal of Veterinary Cardiology, v. 45, p. 27–40, fev. 2023. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S1760273422001217. Acesso em: 4 jul. 2025.
FERNÁNDEZ, D. M.; GONZÁLEZ, A. S. Doença valvar Degenerativa. In: VÁZQUEZ, D. M. P.; GONZÁLEZ, A. J. S. CARDIOLOGIA CLÍNICA DE CÃES E GATOS. São Paulo: Medvet, 2022. p. 145-158.
FERNÁNDEZ, D. M. et al. The Thoracic Inlet Heart Size, a New Approach to Radiographic Cardiac Measurement. Animals, [S.l.], v. 13, n. 3, p. 1–18, 2023. DOI: 10.3390/ani13030389. Disponível em: https://www.mdpi.com/2076-2615/13/3/389. Acesso em: 03 jul. 2025.
FERNÁNDEZ, D. M.; GARCÍA, V.; SANTANA, A. J.; MONTOYA-ALONSO, J. A. The thoracic inlet length as a reference point to radiographically assess cardiac enlargement in dogs with myxomatous mitral valve disease. Animals, Basel, v. 13, n. 16, p. 2666, 2023. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451611/. Acesso em: 3 jul. 2025.
FRANCHINI, A. et al. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics. Journal of Veterinary Cardiology, v. 41, p. 99–120, 2022. Disponível em: https://doi.org/10.1016/j.jvc.2022.02.001. Acesso em: 15 jul. 2025.
HÄGGSTRÖM, J. et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. Journal of Veterinary Internal Medicine, v. 27, n. 6, p. 1441–1451, 2013. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/jvim.12181. Acesso em: 14 ago. 2025.
ISAYAMA, N.; UCHIMURA, Y.; SASAKI, K.; MAEDA, E.; TAKAHASHI, T.; WATANABE, M. Reference values of M-mode echocardiographic parameter in adult toy breed dogs. Frontiers in Veterinary Science, [S. l.], v. 9, p. 1–13, 23 jun. 2022. DOI: 10.3389/fvets.2022.918457. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261867/. Acesso em: 7 jul. 2025.
JEUNG, S.; AN, J-H.; KIM, S-S.; YOUN, H-Y. Safety and efficacy of canine gonadal tissue-derived mesenchymal stem cells for early myxomatous mitral valve disease. Frontiers in Veterinary Science, v. 11, 2024. DOI: 10.3389/fvets.2024.1404607. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11480051/. Acesso em: 22 jul. 2025.
KEENE, B. W. et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine, v. 33, p. 1127–1140, 2019.
KIM, M.; SEO, M.; PARK, C. A novel echocardiographic index (modified-left-atrium-to-aorta ratio) for quantifying left atrial size and differentiating stages in dogs with myxomatous mitral valve disease. Animals, Basel, v. 15, n. 12, p. e1820, 2025. Disponível em: https://www.mdpi.com/2076-2615/15/12/1820. Acesso em: 1 out. 2025.
LAFLAMME, D. P. Key nutrients important in the management of canine myxomatous mitral valve disease and heart failure. Journal of the American Veterinary Medical Association, [S.l.], v. 260, ed. S3, 2022. Disponível em: https://avmajournals.avma.org/view/journals/javma/260/S3/javma.22.07.0319.xml?tab_body=fulltext. Acesso em: 21 jul. 2025.
LAM, C.; GAVAGHAN, B. J.; MEYERS, F. E. Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease. Journal of Veterinary Internal Medicine, [S.l.], v. 35, n. 2, p. 747–754, 2021. Disponível em: https://doi.org/10.1111/jvim.16073. Acesso em: 01 jul. 2025.
LANE, B. et al. High-velocity nasal insufflation in dogs with left-sided congestive heart failure unresponsive to traditional oxygen therapy: a retrospective case series. Frontiers in Veterinary Science, v. 12, p. 1562633, 9 maio 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12098610. Acesso em: 25 ago. 2025.
LJUNGVALL, I.; HÄGGSTRÖM, J. Myxomatous valvular disease. In: BUSSADORI, C. (ed.). Textbook of cardiovascular medicine in dogs and cats. Palm Beach Gardens: Edra Publishing US, 2023. p. 638-702.
MARCHESOTTI, F. et al. Left atrial anteroposterior diameter in dogs: reference interval, allometric scaling, and agreement with the left atrial-to-aortic root ratio. Journal of Veterinary Medical Science, v. 81, n. 11, p. 1655–1662, 14 out. 2019. DOI: 10.1292/jvms.19-0240. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895628/. Acesso em: 6 jul. 2025.
NAIR, S. K.; HERSH, E. V.; MARGULIES, K. B.; DANIELL, H. Clinical studies in Myxomatous Mitral Valve Disease dogs: most prescribed ACEI inhibits ACE2 enzyme activity and ARB increases AngII pool in plasma. Hypertension Research, v. 48, n. 4, p. 1477–1490, 21 jan. 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11972962. Acesso em: 14 ago. 2025.
OGAWA, M. et al. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease. Journal of Veterinary Medical Science, v. 83, n. 4, p. 705–715, 2021. Disponível em: https://doi.org/10.1292/jvms.20-0629. Acesso em: 18 jun. 2025.
OGAWA, M. et al. Evaluation of the association between electrocardiogram parameters and left cardiac remodeling in dogs with myxomatous mitral valve disease. Veterinary World, [S.l.], v. 15, n. 8, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36313845. Acesso em: 30 jun. 2025.
OYAMA, M. A. et al. Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease. Journal of Veterinary Internal Medicine, v. 37, n. 4, p. 1323–1330, jul. 2023. DOI: 10.1111/jvim.16796. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10365052. Acesso em: 31 jul. 2025.
PARK, S. Y.; OH, W-S.; LEE, S. Amlodipine decreases mitral regurgitation volume in dogs over 7 days: A study of 24 dogs with myxomatous mitral valve degeneration. Veterinary Record Open, v. 9, n. 1, e33, 2022. Disponível em: https://bvajournals.onlinelibrary.wiley.com/doi/full/10.1002/vro2.33. Acesso em: 22 jul. 2025.
RISHNIW, M.; BROWN, D. The ACVIM consensus statement definition of left ventricular enlargement in myxomatous mitral valve disease does not always represent left ventricular enlargement. Journal of Veterinary Cardiology, v. 42, p. 92–102, ago. 2022. Disponível em: https://doi.org/10.1016/j.jvc.2022.06.004. Acesso em: 7 jul. 2025.
ROMITO, G. et al. Comparison of the effects of dual, triple, and quadruple medical therapy on cardiac death in a retrospective cohort of dogs with myxomatous mitral valve disease at American College of Veterinary Internal Medicine stage C: is more necessarily better?. Journal of the American Veterinary Medical Association, [S. l.], v. 1, p. 1–11, 20 ago. 2025. DOI: 10.2460/javma.24.09.0588. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40840525/. Acesso em: 14 set. 2025.
SAENGKLUB, N.; PIRINTR, P.; NAMPIMOON, T.; KIJTAWORNAT, A.; CHAIYABUTR, N. Short-term effects of Sacubitril/valsartan on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease. Frontiers in Veterinary Science, v. 8, 2021. Disponível em: https://www.frontiersin.org/articles/10.3389/fvets.2021.700230/full. Acesso em: 27 ago. 2025.
SISSON, D. D. Acute and short-term hemodynamic, echocardiography, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the invasive multicenter PROspective veterinary evaluation of enalapril study: the IMPROVE Study Group. Journal of Veterinary Internal Medicine, v. 9, n. 4, p. 234–242, jul. 1995. Disponível em: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1939-1676.1995.tb01074.x. Acesso em: 12 ago. 2025.
SILVA, Paulo Victor Guimarães Soares da; CARIOCA, Ana Carolina Fernandes; ALVES, Yasmin Carvalho. Edema pulmonar secundário à doença degenerativa da válvula mitral em um cão - relato de caso. Brazilian Journal of Animal and Environmental Research, Curitiba, v. 8, n. 3, p. 1-12, 2025. DOI: 10.34188/bjaerv8n3-015. Disponível em: https://doi.org/10.34188/bjaerv8n3-015. Acesso em: 30 set. 2025.
STAVEREN, M. D. B. van; MUIS, E.; SZATMÁRI, V. Self-Reported Utilization of International (ACVIM Consensus) Guidelines and the Latest Clinical Trial Results on the Treatment of Dogs with Various Stages of Myxomatous Mitral Valve Degeneration: A Survey among Veterinary Practitioners. Animals, v. 14, n. 5, p. 1–23, 2024. Disponível em: https://www.mdpi.com/2076-2615/14/5/772. Acesso em: 15 jul. 2025.
SZCZEPANKIEWICZ, B. et al. Evaluation of the diagnostic value of the renal resistive index as a marker of the subclinical development of cardiorenal syndrome in MMVD dogs. Journal of Renin-Angiotensin-Aldosterone System, [S.l.], v. 22, n. 1, p. 1470320321995082, 17 mar. 2021. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC8010829. Acesso em: 9 jul. 2025.
THE BENCH (BENazepril in Canine Heart disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. Journal of Veterinary Cardiology, v. 1, n. 1, p. 7–18, maio 1999. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S176027340670025X. Acesso em: 12 ago. 2025.
TOALDO, M. B.; ROMITO, G.; GUGLIELMINI, C.; DIANA, A.; PELLE, N. G.; CONTIERO, B.; CIPONE, M. Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease. Journal of Veterinary Internal Medicine, Hoboken, v. 32, n. 3, p. 914–921, 2018. Disponível em: https://doi.org/10.1111/jvim.15093. Acesso em: 8 jul. 2025.
UMEZAWA, M.; FUJII, Y.; ORITO, K.; YOSHIMOTO, R. Sodium-glucose co-transporter 2 inhibitors: prospects for canine myxomatous mitral valve disease and finding the “right drug” and the “right dose” for dogs. Journal of Veterinary Medical Science, v. 87, n. 6, p. 647–666, 16 abr. 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12159257. Acesso em: 28 ago. 2025.
VEZZOSI, T. et al. The Mitral Insufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine, [S.l.], v. 35, n. 3, p. 1238–1244, maio 2021. Disponível em: https://doi.org/10.1111/jvim.16131. Acesso em: 6 jul. 2025.
VEZZOSI, T. et al. Two radiographic methods for assessing left atrial enlargement and cardiac remodeling in dogs with myxomatous mitral valve disease. Journal of Veterinary Cardiology, v. 34, p. 55–63, abr. 2021. Disponível em: https://doi.org/10.1016/j.jvc.2021.01.002. Acesso em: 3 jul. 2025.
WESS, G. et al. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. Journal of Veterinary Internal Medicine, v. 34, n. 6, p. 2232–2241, 2020. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/jvim.15863. Acesso em: 11 ago. 2025.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
- O conteúdo dos artigos é de responsabilidade exclusiva dos autores.
- É permitida a reprodução total ou parcial do conteúdo dos artigos, desde que citada a fonte.
- Artigos com plágio serão recusados, e o autor do plágio perderá o direito de publicar nesta revista.
- Os nomes e endereços informados nesta revista serão utilizados exclusivamente para os serviços prestados por esta publicação e não estão disponíveis para outros fins ou a terceiros.
- Depois de enviar os artigos, os autores cedem os direitos autorais de seus artigos ao BJAER. Se você se arrepender da submissão, o autor tem o direito de solicitar ao BJAER que não publique seu artigo. Porém, essa solicitação deve ocorrer até dois meses antes da divulgação do número que o artigo será publicado.
- O BJAER usa a licença Creative Commons CC BY. Informações sobre esta licença podem ser encontradas em: https://creativecommons.org/licenses/by/3.0/br/
Brazilian Journal of Animal and Environmental Research (BJAER) se reserva o direito de efetuar nos originais alterações de ordem normativa, ortográfica e gramatical, com vistas a manter o padrão culto da língua, respeitando, porém, o estilo dos autores. Os trabalhos finais não serão enviadas aos autores.
